[Expert consensus on renal cell carcinoma with bone metastasis (2020 Edition)].

Bone is the second most common metastatic site of renal cell carcinoma (RCC), about 35-40% of metastatic RCC patients are associated with bone metastasis. Bone metastasis can cause pain, pathological fracture, spinal cord compression, hypercalcemia and other skeletal related events (SREs), which may seriously affect patients' quality of life. RCC patients with bone metastasis, for whom drug therapy alone is less effective and the prognosis is poor, required multi-disciplinary team (MDT) and individualized comprehensive treatment to reduce or delay the onset of SRE, to maintain the quality of life and to extend the time of disease control and survival. In order to update the worldwide treatment progress in RCC with bone metastasis timely, and to improve the standardized diagnosis and treatment of such patients in China, the diagnosis and therapy for bone metastasis of malignant tumor and skeletal-related event expert group formulates "Expert consensus on renal cell carcinoma with bone metastasis (2020 Edition)" .骨转移为肾癌第2常见的转移部位，约35%～40%的转移性肾癌合并骨转移。可致疼痛、病理性骨折、脊髓压迫和高钙血症等骨相关事件(SRE)，严重影响患者的生活质量。肾癌骨转移单纯药物治疗疗效有限，预后不佳，需采用多学科综合治疗模式，制定个体化的综合治疗方案，以减少或延缓SRE的发生，维持患者较好的生存质量，延长疾病控制和生存时间。为提高中国肾癌骨转移患者的规范化诊疗，恶性肿瘤骨转移和骨相关疾病临床诊疗专家组制定了肾癌骨转移专家共识(2020版)。.